Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CCL22 is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Additionally we are shipping CCL22 Antibodies (187) and CCL22 Kits (112) and many more products for this protein.
Showing 10 out of 66 products:
This review presents key clinical studies of Multiple sclerosis together with experimental studies in animals that have demonstrated functional roles of CCR4 (show CCR4 Proteins), CCL17 (show CCL17 Proteins), and CCL22 in experimental autoimmune encephalomyelitis pathogenesis. [review]
MDC (show ADAM11 Proteins) might serve as a marker of pharmacological therapy response in major depressive disorder
Data suggest that high levels of CCL17 (show CCL17 Proteins) and CCL22 in endometrium in women with endometriosis promote (1) recruitment of Tregs, (2) immunosuppression of Tregs, and (3) angiogenesis in endometrium. (Tregs = regulatory T cells)
blood CCL22 levels were positively associated with IgE sensitization at age 2. A high cord blood CCL22/CXCL10 (show CXCL10 Proteins) chemokine (show CCL1 Proteins) ratio was significantly associated with a higher risk of allergic sensitization at age 3.
Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 (show CCR4 Proteins) signaling axis.
Elevations in serum MDC (show ADAM11 Proteins) and BLC (show CXCL13 Proteins) were independently associated with the significant risk of early stage lung adenocarcinoma, even in non-smokers and in stage IA patients.
These results showed that the higher levels of CXCL10 (show CXCL10 Proteins), CCL20 (show CCL20 Proteins) and CCL22 were associated with ischemic heart disease. The serum levels of chemokines may influence by the certain traditional risk factors of IHD and some studied SNPs, but did not influence by treatment and gender of patients.
CCL22 plays an important role in supporting gastric cancer development presumably by increasing the percentage of regulatory T cells in the tumor microenvironments. CCL22 levels in sera have a predictive value for gastric cancer peritoneal metastasis and the early recurrence.
The CCL22-mediated enhancement of antitumor responses is however not due to conversion, but rather to redirection of existing regulatory T cells to the site of cutaneous overexpression.
CCL22 and IL-37 with a co-localization in non-small cell lung cancer A549 cells inhibited the proliferation and epithelial-mesenchymal transition process
the subset of peritoneal CD11b (show ITGAM Proteins)(+)CD169 (show SIGLEC1 Proteins)(+) macrophages increased and CCL22 expression level decreased significantly during the DSS (show PMP22 Proteins)-induced colitis
Intratumoral administration of anti-CCL22 antibody inhibited B16F10 melanoma growth.
this study shows that intravenous injection of apoptotic cells induces a subsequent increase in CCL22 expression and CCR4 (show CCR4 Proteins)+ Treg cells, which contribute to the maintenance of immune homeostasis at least partially by splenic CD8alpha+ CD103 (show ITGAE Proteins)+ dendritic cells
CCL22-specific antibodies reveal that engagement of two distinct binding domains on CCL22 is required for CCR4 (show CCR4 Proteins)-mediated function.
CCL22 was localised mainly on the cell surface and or in the cytoplasm. Within sections of omental milky spot micrometastases, CCR4 (show CCR4 Proteins) was recognised on or in gastric cancer cells, constituent cells milky spots, blood cells and blood endothelial cells
results show that the IL-4 (show IL4 Proteins)/CCL22/CCR4 (show CCR4 Proteins) axis is involved in the migration of Tregs to osteolytic lesion sites, and attenuates development of lesions by inhibiting inflammatory migration and the production of proinflammatory and osteoclastogenic mediators
CCL22 has a role in Treg skin homing to suppress depigmentation
CCL22 is a novel mediator of lung inflammation following hemorrhage and resuscitation
The immunomodulatory properties of CCL22 could be harnessed for prevention of graft rejection and type 1 diabetes as well as other autoimmune disorders.
Data indicate macrophage-derived chemokine CCL22 as an adjuvant could enhance the immune protective effect of NTHi-P6 protein vaccine to an extent.
This gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for monocytes, dendritic cells, natural killer cells and for chronically activated T lymphocytes. It also displays a mild activity for primary activated T lymphocytes and has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes. The product of this gene binds to chemokine receptor CCR4. This chemokine may play a role in the trafficking of activated T lymphocytes to inflammatory sites and other aspects of activated T lymphocyte physiology.
C-C motif chemokine 22
, CC chemokine STCP-1
, macrophage-derived chemokine
, small inducible cytokine A22
, small inducible cytokine subfamily A (Cys-Cys), member 22
, small-inducible cytokine A22
, stimulated T cell chemotactic protein 1
, stimulated T-cell chemotactic protein 1
, CC chemokine ABCD-1
, SMALL INDUCIBLE CYTOKINE A22 PRECURSOR (CC CHEMOKINE ABCD-1) (ACTIVATED B AND DENDRITIC CELL-DERIVED)
, activated B and dendritic cell-derived
, dendritic cell and B cell derived chemokine
, small inducible cytokine subfamily A, member 22
, small inducible cytokine subfamily A22
, small inducible cytokine subfamily A (Cys-Cys) member 22
, chemokine (C-C motif) ligand 22